These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29367463)

  • 21. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
    Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
    Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
    Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
    Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Desmoplasia and oncogene driven acinar-to-ductal metaplasia are concurrent events during acinar cell-derived pancreatic cancer initiation in young adult mice.
    Johnson BL; d'Alincourt Salazar M; Mackenzie-Dyck S; D'Apuzzo M; Shih HP; Manuel ER; Diamond DJ
    PLoS One; 2019; 14(9):e0221810. PubMed ID: 31490946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
    Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
    Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.
    Muzumdar MD; Dorans KJ; Chung KM; Robbins R; Tammela T; Gocheva V; Li CM; Jacks T
    Nat Commun; 2016 Sep; 7():12685. PubMed ID: 27585860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
    Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
    BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesis.
    Matsuura T; Maru Y; Izumiya M; Hoshi D; Kato S; Ochiai M; Hori M; Yamamoto S; Tatsuno K; Imai T; Aburatani H; Nakajima A; Hippo Y
    Carcinogenesis; 2020 Jun; 41(4):490-501. PubMed ID: 31233118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARID1A, a SWI/SNF subunit, is critical to acinar cell homeostasis and regeneration and is a barrier to transformation and epithelial-mesenchymal transition in the pancreas.
    Wang W; Friedland SC; Guo B; O'Dell MR; Alexander WB; Whitney-Miller CL; Agostini-Vulaj D; Huber AR; Myers JR; Ashton JM; Dunne RF; Steiner LA; Hezel AF
    Gut; 2019 Jul; 68(7):1245-1258. PubMed ID: 30228219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism.
    Patra KC; Kato Y; Mizukami Y; Widholz S; Boukhali M; Revenco I; Grossman EA; Ji F; Sadreyev RI; Liss AS; Screaton RA; Sakamoto K; Ryan DP; Mino-Kenudson M; Castillo CF; Nomura DK; Haas W; Bardeesy N
    Nat Cell Biol; 2018 Jul; 20(7):811-822. PubMed ID: 29941929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
    Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
    Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Effect of Driver Mutations of
    Gu Y; Ji Y; Jiang H; Qiu G
    Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of thymic tumor in [LSL:Kras
    Liot S; El Kholti N; Balas J; Genestier L; Verrier B; Valcourt U; Lambert E
    Sci Rep; 2021 Jul; 11(1):15075. PubMed ID: 34302028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long noncoding RNA TP53TG1 promotes pancreatic ductal adenocarcinoma development by acting as a molecular sponge of microRNA-96.
    Zhang Y; Yang H; Du Y; Liu P; Zhang J; Li Y; Shen H; Xing L; Xue X; Chen J; Zhang X
    Cancer Sci; 2019 Sep; 110(9):2760-2772. PubMed ID: 31325400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS
    Principe DR; Overgaard NH; Park AJ; Diaz AM; Torres C; McKinney R; Dorman MJ; Castellanos K; Schwind R; Dawson DW; Rana A; Maker A; Munshi HG; Rund LA; Grippo PJ; Schook LB
    Sci Rep; 2018 Aug; 8(1):12548. PubMed ID: 30135483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 status determines the role of autophagy in pancreatic tumour development.
    Rosenfeldt MT; O'Prey J; Morton JP; Nixon C; MacKay G; Mrowinska A; Au A; Rai TS; Zheng L; Ridgway R; Adams PD; Anderson KI; Gottlieb E; Sansom OJ; Ryan KM
    Nature; 2013 Dec; 504(7479):296-300. PubMed ID: 24305049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.